Fate Therapeutics, Inc.

Fate Therapeutics reported promising initial clinical results for FT819, an off-the-shelf CAR T-cell therapy treating systemic lupus erythematosus, demonstrating significant disease activity reductions and potential for immune system remodeling with minimal conditioning chemotherapy.

Fate Therapeutics announced that clinical data from its ongoing Phase 1 trial of FT819, an off-the-shelf CAR T-cell product candidate, in patients with moderate-to-severe systemic lupus erythematosus (SLE) will be presented at the EULAR 2025 Congress.

Fate Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted restricted stock units representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee and granted under the Company's Amended and Restated Inducement Equity Plan.

The NK cell therapy market is experiencing significant growth, driven by rising interest in immuno-oncology and advancements in cell engineering technologies. Key players are investing in innovative approaches, including combination therapies and gene-modified NK cells, to improve clinical outcomes.

Fate Therapeutics, a clinical-stage biopharmaceutical company, announced that Bob Valamehr, Ph.D. MBA, will assume the role of President and CEO on January 1, 2025, succeeding Scott Wolchko, who will retire after 10 years of leadership. The company will continue its mission to develop novel off-the-shelf cellular immunotherapies.